Skip to Content
Merck
  • Action of nicotine and analogs on acetylcholine receptors having mutations of transmitter-binding site residue αG153.

Action of nicotine and analogs on acetylcholine receptors having mutations of transmitter-binding site residue αG153.

The Journal of general physiology (2013-01-02)
Snehal Jadey, Prasad Purohit, Anthony Auerbach
ABSTRACT

A primary target for nicotine is the acetylcholine receptor channel (AChR). Some of the ability of nicotine to activate differentially AChR subtypes has been traced to a transmitter-binding site amino acid that is glycine in lower affinity and lysine in higher affinity AChRs. We studied the effects of mutations of this residue (αG153) in neuromuscular AChRs activated by nicotine and eight other agonists including nornicotine and anabasine. All of the mutations increased the unliganded gating equilibrium constant. The affinity of the resting receptor (K(d)) and the net binding energy from the agonist for gating (ΔG(B)) were estimated by cross-concentration fitting of single-channel currents. In all but one of the agonist/mutant combinations there was a moderate decrease in K(d) and essentially no change in ΔG(B). The exceptional case was nicotine plus lysine, which showed a large, >8,000-fold decrease in K(d) but no change in ΔG(B). The extraordinary specificity of this combination leads us to speculate that AChRs with a lysine at position αG153 may be exposed to a nicotine-like compound in vivo.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(±)-Nornicotine, ≥98% (TLC), liquid
Supelco
(±)-Nornicotine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®